×

Diclofenac topical formulation

DC CAFC
  • US 8,252,838 B2
  • Filed: 06/05/2008
  • Issued: 08/28/2012
  • Est. Priority Date: 10/17/2006
  • Status: Active Grant
First Claim
Patent Images

1. A topical formulation, said topical formulation consisting essentially of:

  • (i) diclofenac sodium present at 1-2% w/w;

    (ii) DMSO present at 40-50% w/w;

    (iii) ethanol present at 23-29% w/w;

    (iv) propylene glycol present at 10-12% w/w;

    (v) optionally glycerine;

    (vi) a thickening agent, wherein said thickening agent is hydroxypropyl cellulose, the topical formulation having a viscosity of 500-5000 centipoise; and

    (vii) water, wherein said topical formulation when applied to the skin hasa) a greater drying rate; and

    b) a transdermal flux of 1.5 times or greater than a comparative liquid formulation as determined by a Franz cell procedure at finite or infinite dosing, wherein the comparative liquid formulation consists of 1.5% diclofenac sodium, 45.5% dimethylsulfoxide, 11.79% ethanol, 11.2% propylene glycol, 11.2% glycerine, and water.

View all claims
  • 11 Assignments
Timeline View
Assignment View
    ×
    ×